clofibrate and fenofibrate

clofibrate has been researched along with fenofibrate in 109 studies

Research

Studies (109)

Timeframe	Studies, this research(%)	All Research%
pre-1990	42 (38.53)	18.7374
1990's	28 (25.69)	18.2507
2000's	19 (17.43)	29.6817
2010's	17 (15.60)	24.3611
2020's	3 (2.75)	2.80

Authors

Authors	Studies
Bentzen, CL; Nguyen, LM; Niesor, E	1
Branzoli, U; Carganico, G; Chiari, A; Cozzi, P; Lovisolo, PP; Orsini, G; Pillan, A	1
Ashford, A; Ashton, MJ; Loveless, AH; Riddell, D; Salmon, J; Stevenson, GV	1
Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM	1
Henke, BR	1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T	1
Abuo-Rahma, Gel-D; Aly, OM; Idrees, GA; Radwan, MF	1
Chalmers, DK; Chuang, S; Horne, J; Porter, CJ; Scanlon, MJ; Velkov, T; Wielens, J	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Fent, K; Popovic, M; Smital, T; Zaja, R	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y	1
Kritchevsky, D; Story, JA; Tepper, SA	1
Goldberg, DM; Hahn, SE	1
Andreu, T; Auwerx, J; Staels, B; van Tol, A	1
Dorić, M; Gligora, M	1
Schwandt, P	1
Kłosiewicz-Latoszek, L; Szostak, WB	1
Ceska, R; Kvasilová, M; Procházková, R; Sobra, J	1
Bost, M; Boucherle, A; Calop, J; Rossignol, AM	1
Balonová, T; Bencová, E; Durisová, M; Horáková, M; Nosál, R; Onderová, E; Ujházy, E; Zeljenková, D	1
Dostert, P; Hartmann, R; Oesch, F; Schladt, L; Strolin-Benedetti, M; Timms, C; Wörner, W	1
Fournel, S; Magdalou, J; Pinon, P; Siest, G	1
Krause, BR; Newton, RS	1
Bonnefis, MT; Infante, R; Petit, D; Rey, C	1
Blane, GF	1
Palmer, RH	1
Hunninghake, DB; Peters, JR	1
Ginsberg, HN	1
Grundy, SM; Vega, GL	1
Chescoe, D; Grasso, P; Hinton, RH; Price, SC; Wright, M	1
Brown, WV	1
Attianese, R; La Ferla, A; Mascarella, A; Migneco, G	1
Blane, GF; Bridges, JW; Grasso, P; Hall, DE; Hinton, RH; Mitchell, FE; Price, SC	1
Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J	1
Bridges, JW; Hall, DE; Hinton, RH; Mann, A; Mitchell, FE; Price, SC	1
Agar, N; Bousser, MG; Lacombe, C; Mas, JL	1
Bourdeaux, AM; Paris, RM	1
Hamparian, VV; Hughes, JH; Mehl, JK; Witiak, DT	1
Santafé Oroz, J; Segarra Domènech, J	1
Harvengt, C; Heller, F	1
Daubresse, JC	1
Lehmann-Leo, W; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W; Wegscheider, K	1
Borzatta, V; Ciriolo, MR; Cristofari, M; Mavelli, I; Rotilio, G; Stanzani, L	1
Alsasua, MT; Cepeda, L; Gómez, MP	1
Boucherle, A	1
Blane, GF; Pinaroli, F	1
Kritchevsky, D	1
Lutz, WK; Schlatter, C; von Däniken, A	1
Fregnan, GB; Frigerio, L; Porta, R	1
Clouet, E; Paris, R	1
Olsson, AG; Rössner, S	1
Sznajderman, M	1
Barnard, SD; Caldwell, WJ; Lebeau, JE; Molello, JA	1
Calder, D; Luley, C; Scheffler, W; Schilling, A; Schwartzkopff, W	1
Schilling, A; Schwartzkopff, W	1
Ishigami, M; Loo, Y; Sano, K; Sasaki, M; Shin, M; Umezawa, C; Yamashita, Y	1
Cherkaoui Malki, M; el Kebbaj, MH; Latruffe, N	1
Dujovne, CA; Lozada, A	1
Haas, T; Hilgertová, J; Justová, V; Sindelka, G; Skrha, J	1
Betteridge, L; Chan, P; Gallagher, K; Munro, E; Patel, M; Schachter, M; Sever, P; Wolfe, J	1
Beaune, P; Foliot, A	1
Ceska, R; Justová, V; Jůzová, Z; Kvasilová, M; Procházková, R; Sobra, J; Wilczek, H	1
Auwerx, J; Grimaldi, P; Schoonjans, K; Staels, B	1
Bismuth, J; Bonne, J; Gharbi-Chihi, J; Teboul, M; Torresani, J	1
Accatino, L; Amigo, L; Andrade, L; Chianale, J; Gonzalez, S; Nervi, F; Pizarro, M; Rigotti, A; Vollrath, V; Wielandt, AM	1
Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A	1
Auerbach, BJ; Barnett, BC; DeMattos, RB; Essenburg, AD; Haubenwallner, S; Krause, BR; Leff, T; Minton, LL; Newton, RS; Pape, ME	1
Diemer, S; Eberlein-König, B; Przybilla, B	1
Bambauer, R; Müller, UA; Schiel, R	1
Farmer, JA; Gotto, AM	1
Alonso-Galicia, M; Roman, RJ; Wilson, TW	1
Miller, DB; Spence, JD	1
Deyashiki, Y; Hara, A; Ishikura, S; Katagiri, Y; Kato, M; Matsuura, K; Miyabe, Y; Sugiyama, T	1
Kockx, M; Kooistra, T; Princen, HM	1
Alary, J; Costet, P; Debrauwer, L; Dolo, L; Guéraud, F; Paris, A; Pineau, T	1
Derudas, B; Gervois, PP; Gonzalez, FJ; Kockx, M; Kooistra, T; Peters, JM; Poulain, P; Princen, HM; Staels, B	1
Wallace, KB; Zhou, S	1
Berge, RK; Derudas, B; Fruchart, JC; Gervois, P; Guerre-Millo, M; Herbert, JM; Madsen, L; Poulain, P; Raspé, E; Staels, B; Willson, TM; Winegar, DA	1
Idzior-Waluś, B	1
Fujisaki, K; Itoh, Y; Maiguma, T; Makino, K; Oishi, R; Sasaguri, T; Takahashi-Yanaga, F; Teshima, D	1
Maki, KC	1
Cariello, NF; Casey, WM; Colton, HM; Creech, D; Falls, JG; Hamilton, G; Kwanyuen, P; McNeil, E; Ni, H	1
Baldwin, GS; Ford, J; Lachal, S; Shulkes, A	1
Chinetti, G; Fontaine, C; Fruchart, JC; Robillard, R; Staels, B	1
Dragomir, E; Manduteanu, I; Simionescu, M; Tircol, M; Voinea, M	1
Bloomfield, HE	1
Behl, C; Clement, AB; Gamerdinger, M	1
Banks, T; Oyekan, A	1
Calin, M; Dragomir, E; Gan, AM; Koenen, RR; Manduteanu, I; Simionescu, M; Stan, D; Weber, C	1
Kasahara, Y; Koga, S; Miyazaki, M; Nakagawa, I; Patricelli, MP	1
Banfi, C; Brioschi, M; Castiglioni, L; Cimino, M; Gelosa, P; Gianella, A; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E	1
Balendiran, GK; Kotheimer, A; Miller, C; Rath, N; Rath, NP; Zeller, M	1
Abe, S; Hattori, H; Ishizawa, K; Kamiya, M; Kawamura, T; Matsumura, K; Matsushita, T; Miyamoto, L; Nakamoto, A; Nemoto, H; Taoka, C; Tsuchiya, K	1
Henze, E; Müller, GA; Patschan, D; Patschan, S; Scheidemann, R; Schwarze, K	1
Hao, Z; Liu, B; Liu, M; Tao, W; Wang, D	1
Klevay, LM	1
Amagase, Y; Mizukawa, Y; Urushidani, T	1
Chen, Z; Wan, T	1

Reviews

16 review(s) available for clofibrate and fenofibrate

Article	Year
The PPARs: from orphan receptors to drug discovery. Journal of medicinal chemistry, 2000, Feb-24, Volume: 43, Issue:4 Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2000
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17 Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Animals; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Drug Evaluation, Preclinical; Fenofibrate; Humans; Propionates; Random Allocation	1987
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987
Effect of fibric acid derivatives on blood lipid and lipoprotein levels. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Pentanoic Acids	1987
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Anticholesteremic Agents; Apolipoproteins; Clofibrate; Fenofibrate; Humans; Kinetics; Lipoprotein Lipase; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Propionates	1987
Fibric acids: effects on lipids and lipoprotein metabolism. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Bile Acids and Salts; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Pentanoic Acids; Triglycerides	1987
[Pharmacologic therapy of atherosclerosis (I). Current possibilities]. Medicina clinica, 1983, Nov-26, Volume: 81, Issue:17 Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Gemfibrozil; Glycosaminoglycans; Humans; Ion Exchange Resins; Lipoproteins; Nicotinic Acids; Pentanoic Acids; Probucol	1983
Drug interactions with fibric acids. Pharmacology & therapeutics, 1994, Volume: 63, Issue:2 Topics: Anticoagulants; Bezafibrate; Clofibrate; Clofibric Acid; Contraceptives, Oral; Coronary Disease; Drug Interactions; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipids	1994
Choosing the right lipid-regulating agent. A guide to selection. Drugs, 1996, Volume: 52, Issue:5 Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides	1996
Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clinical pharmacokinetics, 1998, Volume: 34, Issue:2 Topics: Anticholesteremic Agents; Clofibrate; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver; Mixed Function Oxygenases; Warfarin	1998
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. Przeglad lekarski, 2001, Volume: 58, Issue:10 Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Insulin Resistance; Lipids; Metabolic Syndrome; Risk Factors	2001
Fibrates for treatment of the metabolic syndrome. Current atherosclerosis reports, 2004, Volume: 6, Issue:1 Topics: Cardiovascular Diseases; Clinical Trials as Topic; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Metabolic Syndrome; Prevalence	2004
Fibrates. Handbook of experimental pharmacology, 2005, Issue:170 Topics: Animals; Atherosclerosis; Bezafibrate; Cholesterol; Clofibrate; Endothelium, Vascular; Fenofibrate; Humans; Hypolipidemic Agents; Lipid Metabolism; PPAR alpha	2005
Fibrates for secondary prevention of cardiovascular disease and stroke. The Cochrane database of systematic reviews, 2015, Oct-25, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cause of Death; Cholesterol, HDL; Clofibrate; Coronary Disease; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypertriglyceridemia; Male; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke	2015

Trials

6 trial(s) available for clofibrate and fenofibrate

Article	Year
Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Animals; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Drug Evaluation, Preclinical; Fenofibrate; Humans; Propionates; Random Allocation	1987
Effects of fibric acid derivatives on biliary lipid composition. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Propionates; Random Allocation	1987
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. Atherosclerosis, 1985, Volume: 54, Issue:3 Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fenofibrate; Fibric Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Propionates; Time Factors	1985
A comparison of fenofibrate and clofibrate hypolipidemic effects. Acta clinica Belgica, 1980, Volume: 35, Issue:4 Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Clofibrate; Fenofibrate; Humans; Hyperlipidemias; Middle Aged; Propionates; Triglycerides	1980
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV]. Die Medizinische Welt, 1982, Apr-30, Volume: 33, Issue:17 Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lipids; Male; Middle Aged; Propionates	1982
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis. The International journal of artificial organs, 1995, Volume: 18, Issue:12 Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life	1995

Other Studies

89 other study(ies) available for clofibrate and fenofibrate

Article	Year
gem-Diphosphonate and gem-phosphonate-phosphate compounds with specific high density lipoprotein inducing activity. Journal of medicinal chemistry, 1987, Volume: 30, Issue:8 Topics: Animals; Chemical Phenomena; Chemistry; Cholesterol, HDL; Diphosphonates; Lipoproteins, HDL; Male; Phosphates; Rats; Rats, Inbred Strains; Structure-Activity Relationship	1987
N-imidazolylchroman-4-ones, N-imidazolyl-1-tetralones, and their alcohols as hypolipemic agents raising high-density lipoproteins. Journal of medicinal chemistry, 1986, Volume: 29, Issue:3 Topics: Alcohols; Animals; Cholesterol; Enzyme Induction; Hypercholesterolemia; Hypolipidemic Agents; Imidazoles; In Vitro Techniques; Lipoproteins, HDL; Liver; Male; Microbodies; Microsomes, Liver; Organ Size; Pyrimidines; Rats; Rats, Inbred Strains; Structure-Activity Relationship	1986
Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity. Journal of medicinal chemistry, 1984, Volume: 27, Issue:10 Topics: Animals; Body Weight; Chemical Phenomena; Chemistry; Cholesterol, Dietary; Eating; Hypolipidemic Agents; Indicators and Reagents; Male; Piperazine; Rats; Rats, Inbred Strains; Structure-Activity Relationship	1984
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
Characterization of the drug binding specificity of rat liver fatty acid binding protein. Journal of medicinal chemistry, 2008, Jul-10, Volume: 51, Issue:13 Topics: Anilino Naphthalenesulfonates; Animals; Fatty Acid-Binding Proteins; Ligands; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Fluorescence; Substrate Specificity	2008
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives. European journal of medicinal chemistry, 2009, Volume: 44, Issue:6 Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypolipidemic Agents; Male; Molecular Structure; Propionates; Rats; Rats, Wistar; Stereoisomerism; Triglycerides	2009
Probing the fibrate binding specificity of rat liver fatty acid binding protein. Journal of medicinal chemistry, 2009, Sep-10, Volume: 52, Issue:17 Topics: Animals; Binding Sites; Carboxylic Acids; Clofibric Acid; Esters; Fatty Acid-Binding Proteins; Fenofibrate; Hypolipidemic Agents; Ligands; Liver; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Rats; Spectrometry, Fluorescence; Substrate Specificity; Temperature; Thermodynamics	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
FDA-approved drug labeling for the study of drug-induced liver injury. Drug discovery today, 2011, Volume: 16, Issue:15-16 Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration	2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide. The Journal of biological chemistry, 2013, Nov-22, Volume: 288, Issue:47 Topics: Animals; Evolution, Molecular; Glycosylation; Gonadal Steroid Hormones; HEK293 Cells; Humans; Ion Transport; Organic Anion Transporters; Protein Multimerization; Zebrafish; Zebrafish Proteins	2013
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16 Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone	2016
[Restrictions also for other lipid-lowering agents?]. MMW, Munchener medizinische Wochenschrift, 1979, Oct-21, Volume: 121, Issue:41 Topics: Clofibrate; Fenofibrate; Germany, West; Legislation, Pharmacy; Patient Compliance	1979
Influence of procetofen on lipid metabolism in normocholesteremic rats. Pharmacological research communications, 1979, Volume: 11, Issue:8 Topics: Absorption; Animals; Cholesterol; Clofibrate; Feces; Fenofibrate; Lipid Metabolism; Liver; Male; Propionates; Rats; Triglycerides	1979
Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochemical pharmacology, 1992, Feb-04, Volume: 43, Issue:3 Topics: Apolipoproteins A; Apolipoproteins B; Carcinoma, Hepatocellular; Cell Line; Cholesterol; Cholesterol Esters; Clofibrate; Dose-Response Relationship, Drug; Fenofibrate; Humans; Lipoproteins, HDL; Lipoproteins, VLDL; Liver Neoplasms; Triglycerides; Tumor Cells, Cultured	1992
Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arteriosclerosis and thrombosis : a journal of vascular biology, 1992, Volume: 12, Issue:3 Topics: Animals; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Apolipoproteins E; Clofibrate; Fenofibrate; Gene Expression; Intestinal Mucosa; Intestines; Kinetics; Liver; Male; Rats; Rats, Inbred Strains; RNA, Messenger; Transcription, Genetic	1992
Further possibilities of using aryloxycarbonic acid derivatives in clinical practice. Folia biologica, 1991, Volume: 37, Issue:2 Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Connective Tissue Diseases; Fenofibrate; Humans; Lymphocyte Activation; Phytohemagglutinins	1991
Fibrates and triglyceride metabolism. European journal of clinical pharmacology, 1991, Volume: 40 Suppl 1 Topics: Bezafibrate; Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Triglycerides	1991
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. European journal of clinical pharmacology, 1991, Volume: 40, Issue:1 Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Probucol	1991
[Etolip and Lipanthyl in the treatment of hyperlipoproteinemia]. Vnitrni lekarstvi, 1990, Volume: 36, Issue:4 Topics: Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Propionates	1990
[Treatment of essential hypercholesterolemia by normolipidemic drugs in children]. Pediatrie, 1989, Volume: 44, Issue:8 Topics: Adolescent; Child; Child, Preschool; Cholestyramine Resin; Clofibrate; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Infant, Newborn; Nicotinic Acids; Sulfur	1989
Teratological study of the hypolipidaemic drugs etofylline clofibrate (VULM) and fenofibrate in Swiss mice. Pharmacology & toxicology, 1989, Volume: 64, Issue:3 Topics: Animals; Body Weight; Clofibrate; Female; Fenofibrate; Fetus; Gestational Age; Hypolipidemic Agents; Mice; Organ Size; Pregnancy; Propionates; Teratogens	1989
Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal beta-oxidation by various hypolipidemic compounds. Biochemical pharmacology, 1987, Feb-01, Volume: 36, Issue:3 Topics: Animals; Aspirin; Clofibrate; Cytosol; Dose-Response Relationship, Drug; Enzyme Induction; Epoxide Hydrolases; Fatty Alcohols; Fenofibrate; Hepatomegaly; Hypolipidemic Agents; Imidazoles; Liver; Male; Microbodies; Microsomes, Liver; Oxidation-Reduction; Palmitoyl-CoA Hydrolase; Probucol; Rats; Rats, Inbred F344	1987
Differential induction profile of drug-metabolizing enzymes after treatment with hypolipidaemic agents. Xenobiotica; the fate of foreign compounds in biological systems, 1987, Volume: 17, Issue:4 Topics: Animals; Biphenyl Compounds; Body Weight; Butyrophenones; Clofibrate; Clofibric Acid; Cytochrome P-450 Enzyme System; Enzyme Induction; Epoxide Hydrolases; Fenofibrate; gamma-Glutamyltransferase; Glucuronosyltransferase; Hypolipidemic Agents; Lipids; Liver; Male; Rats; Rats, Inbred Strains; Structure-Activity Relationship	1987
Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats. Atherosclerosis, 1986, Volume: 59, Issue:1 Topics: Animals; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins E; Bezafibrate; Cholesterol, Dietary; Cholesterol, HDL; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfibrozil; Male; Pentanoic Acids; Rats; Rats, Inbred Strains; Valerates	1986
Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo- and hyperlipidemic rats. Atherosclerosis, 1988, Volume: 74, Issue:3 Topics: Animals; Apolipoproteins; Cholesterol; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hyperlipidemias; Lipids; Lipoproteins; Liver; Male; Propionates; Rats; Rats, Inbred Strains	1988
Alterations in the thyroids of rats treated for long periods with di-(2-ethylhexyl) phthalate or with hypolipidaemic agents. Toxicology letters, 1988, Volume: 40, Issue:1 Topics: Animals; Clofibrate; Diethylhexyl Phthalate; Electron Probe Microanalysis; Fenofibrate; Iodine; Lysosomes; Microscopy, Electron; Phthalic Acids; Plasticizers; Propionates; Rats; Thyroid Gland; Time Factors	1988
Potential use of fenofibrate and other fibric acid derivatives in the clinic. The American journal of medicine, 1987, Nov-27, Volume: 83, Issue:5B Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins, LDL; Propionates	1987
[Clofibrate hepatitis. A case report]. Minerva medica, 1986, May-07, Volume: 77, Issue:19 Topics: Chemical and Drug Induced Liver Injury; Clofibrate; Female; Fenofibrate; Humans; Middle Aged; Time Factors	1986
Time and dose study on the response of rats to the hypolipidaemic drug fenofibrate. Toxicology, 1986, Volume: 41, Issue:2 Topics: Animals; Clofibrate; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Fenofibrate; Hypolipidemic Agents; Kidney; Lipid Metabolism; Liver; Lysosomes; Male; Microbodies; Propionates; Rats; Rats, Inbred Strains; Time Factors	1986
Plasma protein changes in rats treated with hypolipidaemic drugs and with phthalate esters. Human toxicology, 1985, Volume: 4, Issue:3 Topics: Animals; Blood Proteins; Clofibrate; Diet; Diethylhexyl Phthalate; Fenofibrate; Haptoglobins; Hypolipidemic Agents; Immunoelectrophoresis; Male; Phthalic Acids; Rats; Rats, Inbred Strains; Time Factors	1985
Hyperlipidemic dementia. Neurology, 1985, Volume: 35, Issue:9 Topics: Clofibrate; Dementia; Female; Fenofibrate; Humans; Hyperlipidemias; Middle Aged	1985
[Effect of lipid normalizers (clofibrate and procetofene) on chylomicron metabolism in rats]. Archives internationales de physiologie et de biochimie, 1980, Volume: 88, Issue:1 Topics: Animals; Chylomicrons; Clofibrate; Diglycerides; Fenofibrate; Lipid Mobilization; Liver; Male; Organ Size; Propionates; Rats; Triglycerides	1980
Antiviral activity of antilipidemic compounds on herpes simplex virus type 1. Antimicrobial agents and chemotherapy, 1980, Volume: 18, Issue:2 Topics: Antiviral Agents; Clofibrate; Fenofibrate; Hypolipidemic Agents; Simplexvirus; Thymidine; Viral Plaque Assay; Virus Replication	1980
Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. European journal of clinical pharmacology, 1983, Volume: 25, Issue:1 Topics: Adult; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Humans; Hypolipidemic Agents; Lipase; Lipolysis; Lipoprotein Lipase; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Probucol; Triglycerides	1983
Decrease of superoxide dismutase and glutathione peroxidase in liver of rats treated with hypolipidemic drugs. FEBS letters, 1982, Aug-02, Volume: 144, Issue:2 Topics: Animals; Clofibrate; Female; Fenofibrate; Glutathione Peroxidase; Hypolipidemic Agents; Liver; Male; Peroxidases; Rats; Rats, Inbred Strains; Superoxide Dismutase	1982
[Hypolipemic action of various drugs in rats poisoned with Triton WR 1339]. Revista espanola de fisiologia, 1982, Volume: 38 Suppl Topics: Animals; Cholesterol; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Male; Nicotinic Acids; Polyethylene Glycols; Pyridinolcarbamate; Rats	1982
[Fenofibrate: chemical development and differences with clofibrate (author's transl)]. La Nouvelle presse medicale, 1980, Dec-22, Volume: 9, Issue:49 Topics: Animals; Chemical Phenomena; Chemistry; Clofibrate; Fenofibrate; Hypolipidemic Agents; Propionates	1980
[Fenofibrate: animal toxicology in relation to side-effects in man (author's transl)]. La Nouvelle presse medicale, 1980, Dec-22, Volume: 9, Issue:49 Topics: Abnormalities, Drug-Induced; Animals; Biopsy; Clofibrate; Cricetinae; Dogs; Female; Fenofibrate; Humans; Hypolipidemic Agents; Liver; Macaca mulatta; Male; Mice; Mutagens; Pregnancy; Propionates; Rabbits; Rats; Reproduction; Transaminases	1980
[Pharmacology of fenofibrate (author's transl)]. La Nouvelle presse medicale, 1980, Dec-22, Volume: 9, Issue:49 Topics: Animals; Cholesterol; Clofibrate; Dogs; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Kinetics; Propionates; Rats; Triglycerides	1980
Lack of covalent binding to rat liver DNA of the hypolipidemic drugs clofibrate and fenofibrate. Toxicology letters, 1981, Volume: 7, Issue:4-5 Topics: Animals; Carcinogens; Clofibrate; DNA; Female; Fenofibrate; Liver; Male; Propionates; Protein Binding; Rats	1981
Metabolic disorders associated with hyperlipemia: activity of an extremely potent hypolipemic agent (LR 19731). Pharmacology, 1981, Volume: 22, Issue:5 Topics: Animals; Cholesterol; Clofibrate; Dioxoles; Dose-Response Relationship, Drug; Female; Fenofibrate; Hyperlipidemias; Lipids; Liver; Male; Mice; Motor Activity; Nicotinic Acids; Organ Size; Rats; Thyroidectomy; Triglycerides	1981
[Triglyceride synthesis and oleic acid catabolism by hepatic microsomes and mitochondria in clofibrate or procetofen-treated rats]. Reproduction, nutrition, developpement, 1980, Volume: 20, Issue:3A Topics: Animals; Clofibrate; Fenofibrate; Liver; Male; Microsomes, Liver; Mitochondria, Liver; Oleic Acid; Oleic Acids; Propionates; Rats; Rats, Inbred Strains; Triglycerides	1980
Effects of combined procetofene--nicotinic acid therapy in treatment of hypertriglyceridaemia. Atherosclerosis, 1980, Volume: 35, Issue:4 Topics: Aged; Cholesterol; Clofibrate; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Nicotinic Acids; Propionates; Triglycerides	1980
[Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate]. Polskie Archiwum Medycyny Wewnetrznej, 1980, Volume: 63, Issue:6 Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Male; Middle Aged; Propionates; Triglycerides	1980
[Comparative study of the effects of probucol, fenofibrate and clofibrate on liver ultrastructure in rats (author's transl)]. La Nouvelle presse medicale, 1980, Oct-30, Volume: 9, Issue:40 Topics: Animals; Body Weight; Clofibrate; Fenofibrate; Hypolipidemic Agents; Lipids; Liver; Microbodies; Microscopy, Electron; Phenols; Probucol; Propionates; Rats	1980
The effect of etofibrate retard, bezafibrate and procetofen. Artery, 1980, Volume: 8, Issue:2 Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Lipoproteins; Male; Middle Aged; Patient Compliance; Propionates; Triglycerides	1980
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia]. Die Medizinische Welt, 1980, Dec-12, Volume: 31, Issue:50 Topics: Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Male; Middle Aged; Propionates; Triglycerides	1980
Effect of feeding clofibrate-containing diet on the hepatic NAD+ level in rats. Journal of nutritional science and vitaminology, 1995, Volume: 41, Issue:3 Topics: Animals; Clofibrate; Diet; Diethylhexyl Phthalate; Fenofibrate; Hypolipidemic Agents; Liver; Male; Microbodies; NAD; Rats; Rats, Sprague-Dawley	1995
Effect of peroxisomes proliferators and hypolipemic agents on mitochondrial inner membrane linked D-3-hydroxybutyrate dehydrogenase (BDH). Biochemistry and molecular biology international, 1995, Volume: 35, Issue:1 Topics: 2,4-Dichlorophenoxyacetic Acid; Animals; Binding, Competitive; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Hydroxybutyrate Dehydrogenase; Hypolipidemic Agents; In Vitro Techniques; Intracellular Membranes; Male; Microbodies; Mitochondria; Mitochondria, Liver; Phospholipids; Rats; Rats, Wistar; Tetrahymena pyriformis	1995
[Relation between hypertriacylglycerolemia and the action of insulin in type 2 diabetes mellitus]. Casopis lekaru ceskych, 1994, Aug-22, Volume: 133, Issue:16 Topics: Adult; Aged; Clofibrate; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged	1994
Growth inhibition of human vascular smooth muscle cells by fenofibrate: a possible therapy for restenosis. Cardiovascular research, 1994, Volume: 28, Issue:5 Topics: Bezafibrate; Cell Division; Cells, Cultured; Clofibrate; Fenofibrate; Gemfibrozil; Graft Occlusion, Vascular; Humans; Muscle, Smooth; Platelet-Derived Growth Factor; Saphenous Vein	1994
Effects of microsomal enzyme inducers on glutathione S-transferase isoenzymes in livers of rats and hamsters. Biochemical pharmacology, 1994, Jul-19, Volume: 48, Issue:2 Topics: Animals; Clofibrate; Cricetinae; Cytochrome P-450 Enzyme System; Cytosol; Enzyme Induction; Fenofibrate; Glutathione Transferase; Isoenzymes; Male; Microsomes, Liver; Nafenopin; Organ Size; Rats; Rats, Sprague-Dawley; Substrate Specificity	1994
[Therapy with fibrates and vitamin D metabolism]. Casopis lekaru ceskych, 1993, Oct-25, Volume: 132, Issue:20 Topics: Adult; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Vitamin D	1993
Acyl-CoA synthetase mRNA expression is controlled by fibric-acid derivatives, feeding and liver proliferation. European journal of biochemistry, 1993, Sep-01, Volume: 216, Issue:2 Topics: Adipose Tissue; Animals; Clofibrate; Coenzyme A Ligases; Diet; Fenofibrate; Gemfibrozil; Gene Expression Regulation, Enzymologic; Glucocorticoids; Heart; Kidney; Liver; Liver Neoplasms, Experimental; Male; Mice; Microbodies; Myocardium; Oxidation-Reduction; Rats; Rats, Wistar; Repressor Proteins; RNA, Messenger; Saccharomyces cerevisiae Proteins; Tumor Cells, Cultured	1993
Increase of adipose differentiation by hypolipidemic fibrate drugs in Ob 17 preadipocytes: requirement for thyroid hormones. Biochimica et biophysica acta, 1993, May-08, Volume: 1177, Issue:1 Topics: Adipose Tissue; Animals; Bezafibrate; Cell Differentiation; Cell Line; Cell Nucleus; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Mice; Mice, Obese; Receptors, Thyroid Hormone; Thyroid Hormones; Thyroxine	1993
Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. The Biochemical journal, 1996, Mar-15, Volume: 314 ( Pt 3) Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Bezafibrate; Bile; Bile Canaliculi; Clofibrate; Clofibric Acid; DNA Primers; Drug Resistance, Multiple; Fenofibrate; Fibric Acids; Gemfibrozil; Gene Expression; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred Strains; Molecular Sequence Data; Multigene Family; Phospholipids; RNA, Messenger; RNA, Ribosomal, 18S	1996
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat. Israel journal of medical sciences, 1996, Volume: 32, Issue:6 Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin	1996
Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. Journal of lipid research, 1995, Volume: 36, Issue:12 Topics: Animals; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Cholesterol; Clofibrate; Fenofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides	1995
Evaluation of the phototoxic properties of some hypolipidemics in vitro: fenofibrate exhibits a prominent phototoxic potential in the UVA and UVB region. Journal of dermatological science, 1996, Volume: 13, Issue:2 Topics: Bezafibrate; Clofibrate; Dermatitis, Phototoxic; Drug Evaluation, Preclinical; Fenofibrate; Gemfibrozil; Hemolysis; Humans; Hypolipidemic Agents; In Vitro Techniques; Ultraviolet Rays	1996
Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension (Dallas, Tex. : 1979), 1998, Volume: 31, Issue:1 Pt 2 Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Diet, Sodium-Restricted; Enzyme Induction; Female; Fenofibrate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Kidney; Kidney Glomerulus; Male; Mixed Function Oxygenases; Pravastatin; Proteinuria; Rats; Rats, Inbred Strains; Sodium, Dietary; Triglycerides; Weight Gain	1998
Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives. The Journal of pharmacology and experimental therapeutics, 1998, Volume: 285, Issue:3 Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Binding Sites; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Enzyme Activation; Fenofibrate; Humans; Hydrogen-Ion Concentration; Hydroxysteroid Dehydrogenases; Hypolipidemic Agents; Liver	1998
Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha. Thrombosis and haemostasis, 1998, Volume: 80, Issue:6 Topics: 5,8,11,14-Eicosatetraynoic Acid; Alitretinoin; Animals; Apolipoprotein A-I; Cells, Cultured; Clofibrate; Clofibric Acid; Dimerization; Female; Fenofibrate; Fibric Acids; Fibrinogen; Gemfibrozil; Gene Expression Regulation; Genes, Reporter; Hypolipidemic Agents; Liver; Macaca fascicularis; Male; Peroxisome Proliferators; Plasminogen Activator Inhibitor 1; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Receptors, Retinoic Acid; Retinoid X Receptors; Transcription Factors; Transcriptional Activation; Tretinoin	1998
In vivo involvement of cytochrome P450 4A family in the oxidative metabolism of the lipid peroxidation product trans-4-hydroxy-2-nonenal, using PPARalpha-deficient mice. Journal of lipid research, 1999, Volume: 40, Issue:1 Topics: Aldehydes; Animals; Chromatography, High Pressure Liquid; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Female; Fenofibrate; Hydroxylation; Hypolipidemic Agents; Lipid Peroxidation; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbodies; Microsomes, Liver; Mixed Function Oxygenases; Oxidation-Reduction; Rats; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors	1999
Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. Blood, 1999, May-01, Volume: 93, Issue:9 Topics: Animals; Cells, Cultured; Clofibrate; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Fibric Acids; Fibrinogen; Gene Expression Regulation; Hypolipidemic Agents; Kinetics; Liver; Male; Mice; Mice, Knockout; Peroxisome Proliferators; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Transcription, Genetic; Triglycerides	1999
The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicological sciences : an official journal of the Society of Toxicology, 1999, Volume: 48, Issue:1 Topics: Animals; Bezafibrate; Calcium; Clofibrate; Clofibric Acid; Diethylhexyl Phthalate; Energy Metabolism; Fenofibrate; Fibric Acids; Gemfibrozil; Intracellular Membranes; Male; Membrane Potentials; Mitochondria, Liver; Mitochondrial Swelling; Oxygen; Permeability; Peroxisome Proliferators; Pyrimidines; Rats; Rats, Sprague-Dawley; Trichloroethylene	1999
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. The Journal of biological chemistry, 2000, Jun-02, Volume: 275, Issue:22 Topics: Adipose Tissue; Animals; Butyrates; Clofibrate; Fenofibrate; Hypolipidemic Agents; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Obesity; Phenylurea Compounds; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Transcription Factors	2000
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells. Naunyn-Schmiedeberg's archives of pharmacology, 2003, Volume: 367, Issue:3 Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypolipidemic Agents; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma, Embryonal; RNA, Messenger; Simvastatin; Time Factors; Transcription Factors; Tumor Cells, Cultured	2003
Visualization and quantitation of peroxisomes using fluorescent nanocrystals: treatment of rats and monkeys with fibrates and detection in the liver. Toxicological sciences : an official journal of the Society of Toxicology, 2004, Volume: 80, Issue:1 Topics: Animals; Clofibrate; Dose-Response Relationship, Drug; Fenofibrate; Fluorescent Antibody Technique; Frozen Sections; Humans; Immunoblotting; Liver; Macaca fascicularis; Male; Membrane Proteins; Microscopy, Electron; Peroxisomes; Quantum Dots; Rats; Rats, Wistar; Species Specificity	2004
PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells. Regulatory peptides, 2004, Aug-15, Volume: 120, Issue:1-3 Topics: Bezafibrate; Cell Proliferation; Clofibrate; Clofibric Acid; Colorectal Neoplasms; Fenofibrate; Fibric Acids; Gastrins; Gemfibrozil; Humans; Hypolipidemic Agents; Ligands; Peroxisome Proliferator-Activated Receptors; Protein Precursors; Pyrimidines; Radioimmunoassay; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Vasodilator Agents	2004
Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascular pharmacology, 2006, Volume: 44, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line; Chemokine CCL2; Clofibrate; Dose-Response Relationship, Drug; Endothelial Cells; Fenofibrate; Gene Expression Regulation; Glucose; Humans; NADPH Oxidases; NF-kappa B; Onium Compounds; Peroxisome Proliferators; PPAR alpha; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species; Tosylphenylalanyl Chloromethyl Ketone; Transcription Factor RelA	2006
The role of fibrates in a statin world. Archives of internal medicine, 2006, Apr-10, Volume: 166, Issue:7 Topics: Clofibrate; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Peroxisome Proliferator-Activated Receptors	2006
Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production. Molecular pharmacology, 2007, Volume: 72, Issue:1 Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Celecoxib; Cell Line, Tumor; Cell Membrane; CHO Cells; Cholesterol; Clofibrate; Cricetinae; Cricetulus; Cyclooxygenase Inhibitors; Fenofibrate; Mice; Pyrazoles; Sulfonamides	2007
Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. Journal of hypertension, 2008, Volume: 26, Issue:3 Topics: Angiotensin II; Animals; Cardiovascular Agents; Clofibrate; Fenofibrate; Hemodynamics; Male; Models, Animal; Nitric Oxide; PPAR alpha; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2	2008
High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thrombosis and haemostasis, 2008, Volume: 100, Issue:6 Topics: Cell Adhesion; Cells, Cultured; Chemokine CCL2; Chemokine CX3CL1; Clofibrate; Fenofibrate; Flavonoids; Glucose; Humans; I-kappa B Proteins; Imidazoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Monocytes; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NADPH Oxidases; NF-kappa B; NF-KappaB Inhibitor alpha; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR alpha; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-jun; Pyridines; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Transcription Factor AP-1; Up-Regulation	2008
Proteomics analysis of cardiac muscle from rats with peroxisomal proliferator-activated receptor alpha (PPARalpha) stimulation. The Journal of toxicological sciences, 2010, Volume: 35, Issue:1 Topics: Animals; Chromatography, High Pressure Liquid; Clofibrate; Female; Fenofibrate; Heart; Heart Ventricles; Muscle Proteins; Myocardium; Myocytes, Cardiac; PPAR alpha; Proteomics; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry	2010
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats. The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:2 Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; Hypertension; Inflammation; Interleukin-1beta; Kidney Diseases; Ligands; Male; Oxidative Stress; PPAR alpha; Rats; Rats, Inbred SHR; Stroke; Transforming Growth Factor beta	2010
Biomolecular chemistry of isopropyl fibrates. Journal of pharmaceutical sciences, 2012, Volume: 101, Issue:4 Topics: Clofibrate; Drug Design; Fenofibrate; Fibric Acids; Hypolipidemic Agents; Molecular Conformation; Structure-Activity Relationship; Surface Properties	2012
Synthesis of highly water-soluble fibrate derivatives via BGLation. Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20 Topics: Animals; Bezafibrate; Clofibrate; Fenofibrate; Hypolipidemic Agents; Male; Rats; Rats, Sprague-Dawley; Solubility; Triglycerides; Water	2012
Fibrate treatment of eEOCs in murine AKI. Journal of nephrology, 2014, Volume: 27, Issue:1 Topics: Acute Kidney Injury; Animals; Apoptosis; Cell Movement; Cell Survival; Cells, Cultured; Clofibrate; Endothelial Cells; Fenofibrate; Hypolipidemic Agents; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Vascular Endothelial Growth Factor A	2014
Cholesterotropic and cuprotropic chemicals. Journal of the science of food and agriculture, 2020, Volume: 100, Issue:10 Topics: Animals; Ascorbic Acid; Calcium; Cholesterol; Clofibrate; Copper; Diet; Fenofibrate; Fructose; Humans	2020
Peroxisome proliferator-activated receptor α agonist-induced histidine decarboxylase gene expression in the rat and mouse liver. The Journal of toxicological sciences, 2020, Volume: 45, Issue:8 Topics: Animals; Cell Proliferation; Cells, Cultured; Clofibrate; Databases, Genetic; Fenofibrate; Gene Expression; Hepatocytes; Histidine Decarboxylase; Hypertrophy; Liver; Male; Mice; Mice, Inbred C57BL; PPAR alpha; Pyrimidines; Rats; Rats, Sprague-Dawley; Species Specificity	2020
Covalent organic nanospheres modified magnetic nanoparticles for extraction of blood lipid regulators in water samples. Journal of separation science, 2021, Volume: 44, Issue:11 Topics: Clofibrate; Fenofibrate; Lakes; Magnetite Nanoparticles; Nanospheres; Water Pollutants, Chemical	2021